The use of positron emission tomography (pet) in the diagnosis of neurodegenerative diseases of the elderly
DOI:
https://doi.org/10.15448/2357-9641.2017.1.28174Resumo
---Downloads
Referências
Sokoloff L, Reivich M, Kennedy C, et al. The (14 C)-
deoxyglucose method for measurement of local cerebral
glucose utilization: theory, procedure and normal values in
the conscious and anesthetized albino rat. J Neurochem.
;28:897-916.
Pawlik G, Heiss WD. Positron emission tomography and
neuropsychological function. In: Bigler ED, Yeo RA,
Turkheimer E (eds). Neuropsychological function and brain
imaging. New York: Plenum Publ. Corp.; 1989. p. 65-138.
Heiss WD, Zimmermann-Meinzingen S. PET imaging in
the differential diagnosis of vascular dementia. J Neurol Sci.
;322(1-2):268-73.
Mosconi L. Glucose metabolism in normal aging and
Alzheimer’s disease: Methodological and physiological
considerations for PET studies. Clin Transl Imaging.
;1(4):217-33.
Salmon E. Functional brain imaging applications to
differential diagnosis in the dementias. Curr Opin Neurol.
;15(4):439-44.
Mosconi L, et al. FDG-PET changes in brain glucose
metabolism from normal cognition to pathologically
verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging.
;36:811-22.
Herholz K, et al. Discrimination between Alzheimer
Dementia and Controls by Automated Analysis of
Multicenter FDG PET. Neuroimage. 2002;17(1):302-16.
Silverman DH, Small GW, Chang CY, et al. Positron emission
tomography in evaluation of dementia: Regional brain
metabolism and long-term outcome. JAMA. 2001;286(17):
-7.
De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal
formation glucose metabolism and volume losses in MCI
and AD. Neurobiology of aging. 2001;22(4):529-39.
Gauthier S, et al. Mild cognitive impairment. Lancet.
;367:1262-70.
Jeong Y, et al. 18F-FDG PET Findings in Frontotemporal
Dementia: An SPM Analysis of 29 Patients. J Nucl Med.
;46:233-9.
Foster NL, et al. FDG-PET improves accuracy in
distinguishing frontotemporal dementia and Alzheimer’s
disease. Brain. 2007;130:2616-35.
Spehl TS, Hellwig S, Amtage F, et al. Syndrome-Specific
Patterns of Regional Cerebral Glucose Metabolism in
Posterior Cortical Atrophy in Comparison to Dementia
with Lewy Bodies and Alzheimer’s Disease-A [F-18]-Fdg
Pet Study. J Neuroimaging. 2015;25(2):281-8.
Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral
glucose metabolic features of Parkinson disease and
incident dementia: longitudinal study. J Nucl Med. 2011;
(6):848-55.
Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of
cerebral glucose metabolism in frontotemporal dementia:
a longitudinal 18F-FDG-PET-study. Neurobiol aging.
;28(1):42-50.
Mosconi L, et al. Multicenter standardized 18F-FDG
PET diagnosis of mild cognitive impairment, Alzheimer’s
Disease, and other dementias. J Nucl Med. 2008;49(3):
-8.
Gomperts SN, Rentz DM, Moran E, et al. Imaging
amyloid deposition in Lewy body diseases. Neurology.
;71(12):903-10.
Antonini A, et al. Differential diagnosis of parkinsonism
with FDG and PET. Mov Disord. 1998;13:268-74.
Eckert T, et al. FDG PET in the differential diagnosis of
parkinsonian disorders. Neuroimage. 2005;26:912-21.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Direitos Autorais
A submissão de originais para a PAJAR implica na transferência, pelos autores, dos direitos de publicação. Os direitos autorais para os artigos publicados nesta revista são do autor, com direitos da revista sobre a primeira publicação. Os autores somente poderão utilizar os mesmos resultados em outras publicações indicando claramente a PAJAR como o meio da publicação original.
Licença Creative Commons
Exceto onde especificado diferentemente, aplicam-se à matéria publicada neste periódico os termos de uma licença Creative Commons Atribuição 4.0 Internacional, que permite o uso irrestrito, a distribuição e a reprodução em qualquer meio desde que a publicação original seja corretamente citada.
